Xi Wei, Tan Qinxuan, Hou Yingyong, Hu Xiaoyi, Wang Hang, Liu Li, Xia Yu, Bai Qi, Wang Jiajun, Zhou Jianjun, Guo Jianming
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.
Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China.
Cancer Manag Res. 2021 Jul 6;13:5403-5411. doi: 10.2147/CMAR.S315379. eCollection 2021.
Pseudocapsule (PS) of tumor-parenchyma interface (TPI) can be detected by MDCT (ctPS) in renal cell carcinoma (RCC) with exceptions. We aim to study the prognostic implications and histological reflections of no detection of ctPS in RCC.
A total of 210 RCC patients who had MDCT examination and received nephrectomy in our institution were included in the analysis. Absence or presence of ctPS was recognized, and its associations with overall survival (OS) and progression-free survival (PFS), pathological PS (pPS) and vasculature were studied.
A total of 172 (81.9%) patients were recognized to have a ctPS and 38 (18.1%) had no detection of it. They had comparable histology, stage, grade, and necrosis. Patients without a ctPS had significantly shortened overall survival (OS, p = 0.001) and progression-free survival (PFS, p <0.001), the significance of which persisted in multivariable analysis (OS, HR 3.104, p = 0.003; PFS, HR 3.313, p = 0.001). Nearly all tumors (34/38, 89.4%) without a ctPS actually had a pPS being detected and incompleteness of pPS was also irrelevant (p = 0.739). Compared with ctPS presence, those without a ctPS had significantly thinned pPS (0.36 vs 0.43 mm, p = 0.005). In clear-cell histology, those without a ctPS also contained increased vascular density and cross-sectional area of vessels with long diameter ≥200 um in the pPS layer (p = 0.005 and 0.011) and increased vascular density in the 500 um layer outside pPS (p = 0.017).
Absence of ctPS on MDCT significantly increases the risk of adverse clinical outcome in RCC. It is the reflection of a thinner pPS and enriched vasculature of TPI rather than absence of pPS itself.
肾细胞癌(RCC)中肿瘤-实质界面(TPI)的假包膜(PS)可通过多层螺旋CT(MDCT)检测到(ctPS),但也有例外情况。我们旨在研究RCC中未检测到ctPS的预后意义及组织学表现。
分析纳入了在我院接受MDCT检查并接受肾切除术的210例RCC患者。确认有无ctPS,并研究其与总生存期(OS)、无进展生存期(PFS)、病理PS(pPS)及脉管系统的相关性。
共172例(81.9%)患者被确认有ctPS,38例(18.1%)未检测到ctPS。他们在组织学、分期、分级及坏死情况方面具有可比性。未检测到ctPS的患者总生存期(OS,p = 0.001)和无进展生存期(PFS,p <0.001)显著缩短,在多变量分析中其显著性依然存在(OS,风险比[HR] 3.104,p = 0.003;PFS,HR 3.313,p = 0.001)。几乎所有未检测到ctPS的肿瘤(34/38,89.4%)实际上检测到了pPS,且pPS的不完整性也无相关性(p = 0.739)。与存在ctPS相比,未检测到ctPS的患者pPS明显更薄(0.36 vs 0.43 mm,p = 0.005)。在透明细胞组织学中,未检测到ctPS的患者在pPS层中血管密度增加,长径≥200μm的血管横截面积增加(p = 0.005和p = 0.011),在pPS外500μm层中血管密度也增加(p = 0.017)。
MDCT上未检测到ctPS显著增加了RCC不良临床结局的风险。它反映的是pPS更薄及TPI脉管系统丰富,而非pPS本身不存在。